The Role of NADPH Oxidase

Mariam El Assar,José M. La Fuente,Patricia Sosa,Argentina Fernández,Augusto J. Pepe-Cardoso,Juan I. Martínez-Salamanca,Leocadio Rodríguez-Mañas,Javier Angulo
DOI: https://doi.org/10.3390/ijms25063111
IF: 5.6
2024-03-08
International Journal of Molecular Sciences
Abstract:Erectile dysfunction (ED) is a frequent and difficult-to-treat condition in diabetic men. Protein kinase C (PKC) is involved in diabetes-related vascular and cavernosal alterations. We aimed to evaluate the role of PKC in endothelial dysfunction and NO/cGMP impairment associated with diabetic ED in the human corpus cavernosum (CC) and penile resistance arteries (PRAs) and the potential mechanisms involved. Functional responses were determined in the CC and PRAs in patients with non-diabetic ED and diabetic ED undergoing penile prosthesis insertion. PKC activator 12,13-phorbol-dibutyrate (PDBu) impaired endothelial relaxations and cGMP generation in response to acetylcholine in the CC from non-diabetic ED. PDBu also impaired responses to a PDE5 inhibitor, sildenafil, in non-diabetic ED patients. Conversely, a PKC inhibitor, GF109203X, improved endothelial, neurogenic, and PDE5-inhibitor-induced relaxations and cGMP generation only in the CC in diabetic ED patients. Endothelial and PDE5-inhibitor-induced vasodilations of PRAs were potentiated only in diabetes. Improvements in endothelial function in diabetes were also achieved with a specific inhibitor of the PKCβ2 isoform or an NADPH-oxidase inhibitor, apocynin, which prevented PDBu-induced impairment in non-diabetic patients. PKC inhibition counteracted NO/cGMP impairment and endothelial dysfunction in diabetes-related ED, potentially improving response to PDE5 inhibition.
biochemistry & molecular biology,chemistry, multidisciplinary
What problem does this paper attempt to address?
The paper primarily explores the role of Protein Kinase C (PKC) in diabetes-related erectile dysfunction (ED) and its impact on the nitric oxide/cyclic guanosine monophosphate (NO/cGMP) pathway. The study specifically attempts to address the following key issues: 1. **The role of PKC in diabetes-related erectile dysfunction**: The study aims to evaluate the role of PKC in endothelial dysfunction and NO/cGMP pathway impairment in the corpus cavernosum (CC) and penile resistance arteries (PRA) of diabetic patients with erectile dysfunction. 2. **The effect of PKC inhibitors on endothelial function**: The research investigates how PKC inhibitors improve endothelium-dependent relaxation responses and neurogenic relaxation responses in diabetic patients, and explores the underlying mechanisms. 3. **The relationship between PKC and NADPH oxidase**: The study analyzes the potential role of NADPH oxidase in PKC-related effects, particularly regarding the impact of oxidative stress on vascular function. 4. **The effect of PKC inhibitors on the efficacy of PDE5 inhibitors**: The research evaluates whether PKC inhibitors can enhance the therapeutic effects of PDE5 inhibitors (such as sildenafil) in diabetic patients with erectile dysfunction. In summary, this paper investigates the role of PKC in diabetes-related erectile dysfunction through a series of experiments and explores the potential of PKC inhibition as a therapeutic approach. The results indicate that PKC inhibition can improve endothelial function in diabetic patients, enhance the efficacy of PDE5 inhibitors, and potentially improve erectile function by modulating the NO/cGMP pathway.